Polymorphism of TS 3′-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical and Translational Oncology

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12094-012-0979-8PMID 23263912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers in ovarian cancer risk.

  2012cited by this paper
• Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma

  2011influential reference
• Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

  2011cited by this paper
• Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer

  2010cited by this paper
• Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer

  2010cited by this paper
• Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy

  2010cited by this paper
• Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis.

  2010cited by this paper
• Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

  2009cited by this paper
• A Meta-Analysis

  2009cited by this paper
• Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

  2009cited by this paper
• Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens

  2009cited by this paper
• Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.

  2009cited by this paper
• Polymorphism of thymidylate synthase gene and chemosensitivity of 5‐fluorouracil regimen in metastatic gastrointestinal cancer

  2009cited by this paper
• The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population

  2009cited by this paper
• C677T and A1298C mutations in the MTHFR gene and survival in colorectal cancer.

  2009cited by this paper
• A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

  2008cited by this paper
• Capecitabine and oxaliplatin for advanced esophagogastric cancer.

  2008cited by this paper
• Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer.

  2008cited by this paper
• Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and susceptibility to gastric adenocarcinoma in an Italian population

  2007cited by this paper
• The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours.

  2006cited by this paper
• Methylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico.

  2006cited by this paper
• Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

  2006cited by this paper
• Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance

  2006cited by this paper
• Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients

  2004cited by this paper
• Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase.

  2003cited by this paper
• Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.

  2003cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency

  1999cited by this paper
• Mutations at codon 974 of the DPYD gene are a rare event.

  1997cited by this paper
• Mutations at codon 974 of the DPYD gene are a rare event.

  1997cited by this paper

• Association study of TYMS gene expression with TYMS and ENOSF1 genetic variants in neoadjuvant chemotherapy response of gastric cancer

  2024cites this paper
• Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial

  2022cites this paper
• Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2021cites this paper
• Methylenetetrahydrofolate reductase polymorphism and capecitabine-induced toxicity in patients with gastric cancer

  2020cites this paper
• Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer

  2017cites this paper
• Efficacy and safety of accelerated partial breast irradiation: a meta-analysis of published randomized studies

  2017cites this paper
• Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.

  2017cites this paper
• Association between polymorphisms of thymidylate synthase gene 5′- and 3′-UTR and gastric cancer risk: meta-analysis

  2016cites this paper
• Secondary malignancies after partial versus whole breast irradiation: a systematic review and meta-analysis

  2016cites this paper
• Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

  2016cites this paper
• Nucleoside analogs: ready to enter the era of precision medicine?

  2016cites this paper
• Mechanisms of Resistance to Chemotherapy in Gastric Cancer.

  2016cites this paper
• The role of pharmacogenetics in capecitabine efficacy and toxicity.

  2016cites this paper
• Genetic polymorphisms in the microRNA binding‐sites of the thymidylate synthase gene predict risk and survival in gastric cancer

  2015cites this paper
• [Pharmacogenomics of the first-line treatment for gastric cancer: advances in the identification of genomic biomarkers for clinical response to chemotherapy].

  2014cites this paper
• Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.

  2014cites this paper
• Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics.

  2013cites this paper